NCT03316144View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

September 15, 2018

Study Completion Date

December 30, 2019

Conditions
Malignant Lymphoma
Interventions
BIOLOGICAL

Toripalimab

Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.

Trial Locations (1)

300020

Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT03316144 - Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | Biotech Hunter | Biotech Hunter